Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4971
Name myelofibrosis
Definition A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.
Source DiseaseOntology.org
Alt Ids DOID:5737
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myelofibrosis

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK2 V617F N/A myelofibrosis not applicable detail...
IDH1 mutant N/A myelofibrosis not applicable detail...
IDH2 mutant N/A myelofibrosis not applicable detail...
DNMT3A mutant N/A myelofibrosis not applicable detail...
CBL mutant N/A myelofibrosis not applicable detail...
JAK2 V617F INCB053914 myelofibrosis predicted - sensitive detail...
JAK2 mutant N/A myelofibrosis not applicable detail...
TET2 mutant N/A myelofibrosis not applicable detail...
JAK2 V617F C220 myelofibrosis predicted - sensitive detail...
NRAS mutant N/A myelofibrosis not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01398462 Phase I CWP232291 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Completed USA 1
NCT01644110 Phase Ib/II Pomalidomide + Ruxolitinib Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC) Active, not recruiting DEU 0
NCT01787487 Phase II Azacitidine + Ruxolitinib Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm Recruiting USA 0
NCT02098161 Phase II LCL161 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis Active, not recruiting USA 0
NCT02158858 Phase Ib/II CPI-0610 + Ruxolitinib CPI-0610 A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Recruiting USA | ITA | FRA | DEU | CAN | BEL 3
NCT02251821 Phase II Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Recruiting USA 0
NCT02268253 Phase II Tagraxofusp-erzs Tagraxofusp (SL-401) in Patients With CMML or MF Recruiting USA | CAN 0
NCT02386800 FDA approved Ruxolitinib Panobinostat + Ruxolitinib CINC424A2X01B Rollover Protocol Recruiting ITA | FRA | ESP | DEU | BEL 21
NCT02421354 Phase II Nivolumab Study of Nivolumab in Patients With Myelofibrosis Terminated USA 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA 1
NCT02493530 Phase I Ruxolitinib + Umbralisib TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Active, not recruiting USA 0
NCT02528877 Phase I Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Withdrawn USA 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Recruiting USA 0
NCT02530619 Phase I Alisertib Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia Active, not recruiting USA 0
NCT02564536 Phase I Decitabine + Pacritinib Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Withdrawn 0
NCT02718300 Phase II Parsaclisib + Ruxolitinib A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting USA 0
NCT02966353 Phase II Ruxolitinib Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE) Completed ITA | ESP | DEU | CAN | BEL | AUT 5
NCT03042689 Phase I Regorafenib Study of Regorafenib in Patients With Advanced Myeloid Malignancies Active, not recruiting USA 0
NCT03065400 Phase II Pembrolizumab PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Completed USA 0
NCT03136185 Phase II IMG-7289 IMG-7289 in Patients With Myelofibrosis Completed USA | ITA | DEU 2
NCT03144687 Phase II Itacitinib + Ruxolitinib Itacitinib A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Completed USA | AUT 1
NCT03165734 Phase II Lenalidomide Ruxolitinib Hydroxyurea Pacritinib Thalidomide A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) Recruiting USA | ITA | FRA | ESP | DEU | CAN 13
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Active, not recruiting USA 0
NCT03326310 Phase I Azacitidine + Selumetinib Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia Recruiting USA 0
NCT03373877 Phase I PU-H71 + Ruxolitinib Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis Terminated USA 0
NCT03441113 Phase II Momelotinib Extended Access of Momelotinib in Adults With Myelofibrosis Enrolling by invitation USA | ITA | FRA | ESP | DEU | CAN | BEL 12
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting USA 0
NCT03592576 Expanded access Navitoclax Expanded Access to Navitoclax Available 0
NCT03627403 Phase II Selinexor Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL) Recruiting USA 0
NCT03645824 Phase II Pacritinib Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF) Recruiting BEL 1
NCT03662126 Phase II KRT-232 KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor Recruiting USA | ITA | FRA | ESP | DEU | CAN 15
NCT03755518 Phase III Fedratinib An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM) Active, not recruiting USA | CAN 0
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03886831 Phase I PRT543 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Active, not recruiting USA 0
NCT03895112 Phase I BMS-986416 MPN-RC 118 AVID200 in Myelofibrosis Active, not recruiting USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Recruiting USA 0
NCT03935555 Phase I PU-H71 Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib Recruiting USA 0
NCT03952039 Phase III Fedratinib An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2) Recruiting ITA | FRA | ESP | DEU | BEL | AUT 10
NCT04041050 Phase I Navitoclax Navitoclax + Ruxolitinib A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Recruiting USA | ITA | FRA | ESP | DEU | BEL 9
NCT04089449 Phase I PRT811 A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis Recruiting USA 0
NCT04173494 Phase III Danazol Momelotinib A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 14
NCT04176198 Phase I TP-3654 A Study of Oral TP-3654 in Patients With Myelofibrosis Recruiting USA 1
NCT04279847 Phase I INCB057643 Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis Recruiting USA | ITA | ESP | CAN 3
NCT04281498 Phase II Enasidenib + Ruxolitinib Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Recruiting USA | CAN 0
NCT04282187 Phase II Decitabine + Fedratinib Decitabine + Ruxolitinib Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Recruiting USA 0
NCT04454658 Phase I ABBV-744 ABBV-744 + Navitoclax ABBV-744 + Ruxolitinib Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis Recruiting USA | ITA | ESP 13
NCT04468984 Phase III Navitoclax + Ruxolitinib Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 21
NCT04472598 Phase III Ruxolitinib Navitoclax + Ruxolitinib Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT04480086 Phase I Mivebresib + Navitoclax Mivebresib + Ruxolitinib Mivebresib Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis Active, not recruiting USA 2
NCT04485260 Phase Ib/II KRT-232 + Ruxolitinib An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib Recruiting USA | ITA | FRA | ESP | DEU 4
NCT04517851 Phase I Elotuzumab Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis Recruiting USA 0
NCT04551053 Phase III Parsaclisib + Ruxolitinib Ruxolitinib To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 12
NCT04551066 Phase III Ruxolitinib Parsaclisib + Ruxolitinib To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 10
NCT04576156 Phase III Thalidomide Danazol Hydroxyurea Imetelstat A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 20
NCT04603495 Phase III CPI-0610 + Ruxolitinib Ruxolitinib Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2) Recruiting USA | ITA | FRA | ESP | CAN | BEL | AUT 7
NCT04629508 Phase II Itacitinib To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. Active, not recruiting USA | ITA | ESP | DEU | BEL | AUT 1
NCT04817007 Phase I BMS986158 + Ruxolitinib BMS986158 + CYC065 BMS986158 A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) Recruiting USA | ITA | FRA | ESP | DEU 2
NCT04878003 Phase II TL-895 KRT-232 Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naive Myelofibrosis Recruiting USA 8
NCT04955938 Phase I Enasidenib + Fedratinib Fedratinib + Ivosidenib A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Recruiting USA 0
NCT05127174 Phase Ib/II Fedratinib Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms Recruiting USA 0